<DOC>
	<DOCNO>NCT02759107</DOCNO>
	<brief_summary>The main purpose study determine : - The safety LY3298176 side effect might associate . - How much LY3298176 get bloodstream long take body get rid . - How LY3298176 affect level blood sugar . This study include 3 part ( A , B C ) . Part A involve single dose LY3298176 take subcutaneous ( SC ) injection skin approximately 10 week duration , include screen . Parts B C involve 4 dos LY3298176 take weekly ( 4 week ) SC injection skin approximately 12-14 week duration , include screen . Each participant enroll one part . This study research purpose , intend treat medical condition .</brief_summary>
	<brief_title>A Study LY3298176 Healthy Participants Participants With Type 2 Diabetes ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Healthy participant ( Parts A B ) participant T2DM diagnose least 1 year enrollment ( Part C ) Have screen body mass index ( BMI ) great 18.5 less equal 40.0 kilogram per meter square ( kg/mÂ² ) , inclusive Participants T2DM ( Part C ) : T2DM control diet exercise alone stable single oral antidiabetic medication ( metformin least 30 day sulfonylureas ) . Participants receive sulfonylurea may participate treatment stop least 6 week dose study drug Have know allergy LY3298176 , glucagonlike peptide ( GLP ) 1 analog , relate compound Have abnormality 12lead electrocardiogram ( ECG ) screening , opinion investigator , increase risk associate participate study Have history presence pancreatitis ( history chronic pancreatitis idiopathic acute pancreatitis ) , elevation serum amylase lipase ( great 2fold upper limit normal [ ULN ] ) gastrointestinal ( GI ) disorder ( example , relevant esophageal reflux gall bladder disease ) GI disease impact gastric emptying ( example , gastric bypass surgery , pyloric stenosis , exception appendectomy ) could aggravate glucagonlike peptide1 ( GLP1 ) analogs dipeptidyl peptidase ( DPP ) IV inhibitor Participants T2DM ( Part C ) Have 1 episode severe hypoglycemia , define American Diabetes Association criterion , within 6 month entry study history hypoglycemia unawareness poor recognition hypoglycemic symptom All Study Participants ( Parts B C ) know allergy LY3298176 , GLP1 analog , related compound , acetaminophen</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>